Primary Sclerosing Cholangitis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (PSC)
The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC). Percentage of subjects who show improvement of severity of PSC as assessed by Magnetic Resonance Cholangiopancreatography(MRCP) at Week 12 from baseline, with improvement defined as a decrease of -1 or more in the MRCP and change of alkaline phosphatase(ALP) level will be assessed at Week 12 from baseline.
Sclerosing cholangitis is a rare, chronic, cholestatic liver disease caused by inflammation and fibrosis of the intrahepatic/extrahepatic biliary tract. Its pathophysiology involves destruction and stricture of the bile duct due to diffuse inflammation and fibrosis of the bile duct. The selected subjects will be randomly assigned to either active or placebo groups and administered 100 mg of HK-660S or placebo (1 tablet) twice a day for 12 weeks. After Visit 2, subjects will visit the study center at Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5 / End of Treatment), and Week 16 (Visit 6 / Follow-up) to assess efficacy and safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02239211 -
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
| Withdrawn |
NCT03216876 -
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
|
Phase 1 | |
| Recruiting |
NCT02605213 -
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
|
Phase 4 | |
| Recruiting |
NCT01688024 -
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
| Completed |
NCT03041662 -
Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
|
||
| Recruiting |
NCT05618145 -
National Database on Primary Sclerosing Cholangitis (PSC)
|
||
| Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
| Completed |
NCT02247934 -
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
|
N/A | |
| Completed |
NCT01088607 -
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
|
Phase 1 | |
| Terminated |
NCT01142323 -
Pilot Study of Fenofibrate for PSC
|
Phase 1/Phase 2 | |
| Terminated |
NCT04060147 -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
|
Phase 1 | |
| Recruiting |
NCT04133792 -
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
|
Phase 3 | |
| Active, not recruiting |
NCT04595825 -
CM-101 in PSC Patients -The SPRING Study
|
Phase 2 | |
| Recruiting |
NCT03183570 -
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
|
Early Phase 1 | |
| Completed |
NCT02943460 -
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
|
Phase 2 | |
| Completed |
NCT00951327 -
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
|
N/A | |
| Completed |
NCT04024813 -
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
|
Phase 2 | |
| Recruiting |
NCT05912387 -
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
|
Early Phase 1 | |
| Completed |
NCT02884557 -
NKT Role in the Regulation of the Inflammatory Bowel Disease
|
N/A | |
| Recruiting |
NCT01398917 -
Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis
|
Phase 3 |